Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...5253545556575859606162...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date, Metastases:  CIFRA: Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (clinicaltrials.gov) -  Sep 2, 2021   
    P2,  N=34, Recruiting, 
    These findings highlight the need for research on preventive measures for such rashes. Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Mar 2021 --> Mar 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date, Checkpoint inhibition, Metastases:  Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure (clinicaltrials.gov) -  Aug 31, 2021   
    P2,  N=50, Recruiting, 
    Trial completion date: May 2022 --> May 2025 | Trial primary completion date: May 2021 --> May 2024 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, Imbruvica (ibrutinib) / AbbVie, J&J
    Trial completion date, Trial primary completion date, Combination therapy, IO biomarker, Metastases:  Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC (clinicaltrials.gov) -  Aug 30, 2021   
    P2,  N=39, Recruiting, 
    Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: May 2022 --> May 2023 | Trial primary completion date: May 2021 --> Jun 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Preclinical, Journal:  Bilberry (Vaccinium myrtillus L.) Powder Has Anticarcinogenic Effects on Oral Carcinoma In Vitro and In Vivo. (Pubmed Central) -  Aug 28, 2021   
    The effects of 0, 1, 10, and 25 mg/mL of whole bilberry powder on the viability, proliferation, migration, and invasion of OSCC (HSC-3) cells were examined and compared with 0.01 mg/mL of cetuximab...Compared to controls, the tumor area in zebrafish treated with bilberry powder (10 and 25 µg/mL) was reduced significantly (p = 0.038 and p = 0.021, respectively), but the number of fish with metastases did not differ between groups. Based on our in vitro and in vivo experiments, we conclude that whole bilberry powder has anti-tumor effects on OSCC cells.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors. (Pubmed Central) -  Aug 28, 2021   
    For many years, a combination of platinum-based chemotherapy and anti-EGFR antibody cetuximab has represented the only available option for first-line therapy...In fact, no-chemo options and some molecular targets are on the horizon. This narrative review addresses past, present, and future therapeutic options for HNSCC from a translational point of view.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Preclinical, Journal:  PUM1 Is Overexpressed in Colon Cancer Cells With Acquired Resistance to Cetuximab. (Pubmed Central) -  Aug 28, 2021   
    Furthermore, suppression of DDX5 also decreased the proliferation of SW480R and Caco-2R cells. Our study suggests that PUM1 positively regulates DDX5 and acts as a promoter in cetuximab-resistant colon cancer cells.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    PK/PD data, Journal, PD(L)-1 Biomarker, IO biomarker:  A Pretargeted Imaging Strategy for EGFR-Positive Colorectal Carcinoma via Modulation of Tz-Radioligand Pharmacokinetics. (Pubmed Central) -  Aug 27, 2021   
    Our novel pretargeted imaging strategy (cetuximab-TCO/[Tc]HYNIC-polypeptide-PEG-Tz) was useful for imaging CRC, broadening the application scope of pretargeted imaging strategy. The pretargeted imaging strategy clearly delineated HCT116 tumor, showing that its use could be extended to selection of internalizing antibodies.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs. (Pubmed Central) -  Aug 27, 2021   
    However, this adaptation was always prevented by the addition of selective CDK8/19 inhibitors, even though such inhibitors alone had only moderate or no effect on cell growth. These results indicate that combining EGFR-targeting drugs with CDK8/19 inhibitors may delay or prevent the development of tumor resistance to therapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  Acoustic Droplet-Assisted Superhydrophilic-Superhydrophobic Microarray Platform for High-Throughput Screening of Patient-Derived Tumor Spheroids. (Pubmed Central) -  Aug 25, 2021   
    Using three conventional chemotherapeutics (5-fluorouracil, cetuximab, and panitumumab) of various concentrations, the best treatment was screened out and compared with the actual treatment effect of the patients, and the results were extremely similar. As a proof-of-concept application, we have proved that our platform can quickly cultivate patient samples and effectively screen the best treatment methods, highlighting its wide application in precision medicine, basic tumor research, and drug development.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
    Journal:  Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer. (Pubmed Central) -  Aug 24, 2021   
    Additionally, we illustrate objective responses in reducing tumors at metastatic sites in host animals. The data support the approach of amplifying anti-tumor immunity that may be relevant in combination with other immune modifying therapies such as checkpoint inhibitors.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, PD(L)-1 Biomarker:  Overcoming hypoxia-induced functional suppression of NK cells. (Pubmed Central) -  Aug 22, 2021   
    The potent cytolytic function of haNK cells was maintained in an environment comparable to what would be encountered in a tumor. The data presented here provide an additional mechanism of action for haNK cells that are currently being evaluated in clinical trials for several tumor types.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  lncRNA PVT1 promotes cetuximab resistance of head and neck squamous cell carcinoma cells by inhibiting miR-124-3p. (Pubmed Central) -  Aug 22, 2021   
    The data presented here provide an additional mechanism of action for haNK cells that are currently being evaluated in clinical trials for several tumor types. PVT1 decreased the sensitivity of HNSCC cells to cetuximab by enhancing methylation-mediated inhibition of miR-124-3p, which might provide a new insight for the cetuximab chemoresistance of HNSCC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Exploring the Application of Bifunctional Metal Chelators in Treating Triple-Negative Breast Cancer. (Pubmed Central) -  Aug 21, 2021   
    The tumour inhibition rate of the Lu-3,4-HOPO-Cetuximab and Lu-DOTA-Cetuximab were (37.03 ± 11.16)% and (38.7 ± 5.1)%; HE staining showed that tumour cells were affected by the action of Lu causing necrosis. The experiments showed that Lu-3,4-HOPO-Cetuximab has a certain targeted therapeutic ability for triple-negative breast cancer, and it is expected to become a potential targeted nuclear medicine treatment for triple-negative breast cancer.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  The Conversion of RAS Status in Metastatic Colorectal Cancer Patients After First-Line Biological Agent Treatment. (Pubmed Central) -  Aug 20, 2021   
    Ex vivo evaluation of ADCC, circulating DNA levels and early skin toxicity may predict response to cetuximab plus avelumab in NSCLC.EUDRACT 2017-004195-58. Our results suggest that re-biopsy is needed for an optimal second-line treatment decision in mCRC patients regardless of backbone biological agent, especially in patients with wild-type RAS mCRC.
  • ||||||||||  BMS-986315 / BMS, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS
    Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Aug 20, 2021   
    P1/2,  N=308, Recruiting, 
    Our results suggest that re-biopsy is needed for an optimal second-line treatment decision in mCRC patients regardless of backbone biological agent, especially in patients with wild-type RAS mCRC. Trial completion date: Apr 2024 --> Oct 2024 | Trial primary completion date: Apr 2024 --> Jul 2023
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Head and neck squamous cell carcinoma. (Pubmed Central) -  Aug 20, 2021   
    Elucidation of the molecular genetic landscape of HNSCC over the past decade has revealed new opportunities for therapeutic intervention. Ongoing efforts aim to integrate our understanding of HNSCC biology and immunobiology to identify predictive biomarkers that will enable delivery of the most effective, least-toxic therapies.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Zelboraf (vemurafenib) / Roche
    Trial completion date, Trial primary completion date, Metastases:  Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT) (clinicaltrials.gov) -  Aug 19, 2021   
    P2,  N=30, Recruiting, 
    Ongoing efforts aim to integrate our understanding of HNSCC biology and immunobiology to identify predictive biomarkers that will enable delivery of the most effective, least-toxic therapies. Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
  • ||||||||||  feladilimab (GSK3359609) / GSK
    Trial primary completion date, Combination therapy, Metastases:  GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors (clinicaltrials.gov) -  Aug 18, 2021   
    P1/2,  N=26, Active, not recruiting, 
    These multifunctional nanoparticles may have promising potential for targeted and effective therapy against EGFR-highexpressing cells of epidermoid carcinoma. Trial primary completion date: Aug 2022 --> Jun 2021
  • ||||||||||  CIML NK - Dana / Farber Cancer Institute
    Trial completion date, Trial primary completion date, Combination therapy, Metastases, Immune cell:  CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov) -  Aug 18, 2021   
    P1,  N=12, Recruiting, 
    Recruiting --> Suspended Trial completion date: Sep 2022 --> May 2022 | Trial primary completion date: Sep 2021 --> Apr 2022